Yesway, Inc.: the filing proof gates that matter now
Yesway, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
603Results20Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Aethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clock
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAdagio Medical: the $12.9M cash clock behind a make-or-break VT filing
Adagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
OpenAcurx: the CDI antibiotic bet racing a cash clock
Acurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution become
OpenActuate Therapeutics: the survival signal with a July cash wall
Actuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAcrivon Therapeutics: the cancer-data story with a 2026 readout clock
Acrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.
OpenAclaris Therapeutics: the three-shot catalyst stack racing the cash clock
Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenZevra Therapeutics, Inc.: the filing proof gates that matter now
Zevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenYum China: the KFC China engine still has to beat traffic and capex math
Yum China reported FY2025 revenue of $11.8 billion and Q1 2026 revenue of $3.3 billion. The thesis depends on same-store demand, restaurant expansion, delivery economics, China consumer conditions, margin control and capex discipline.
OpenYatra Online, Inc.: the filing proof gates that matter now
Yatra Online, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZscaler: the zero-trust growth story still has to turn into clean GAAP profit
Zscaler reported FY2025 revenue of $2.7 billion and Q2 FY2026 revenue of $815.8 million. The thesis depends on zero-trust demand, large-customer expansion, billings quality, operating leverage, stock compensation and cash conversion.
OpenZentalis Pharmaceuticals, Inc.: the filing proof gates that matter now
Zentalis Pharmaceuticals, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZoom: the cash-rich meeting platform has to prove AI can restart durable growth
Zoom reported FY2026 revenue of $4.9 billion and Q3 FY2026 revenue of $1.2 billion. The thesis depends on enterprise retention, Zoom Phone, contact center, AI features, margin durability and cash conversion.
OpenKinder Morgan: the pipeline cash machine still lives under a leverage ceiling
Kinder Morgan reported 2025 revenue of $15.20 billion, operating income of $4.72 billion and operating cash flow of $5.92 billion. The Coverage Bootstrap question is whether natural-gas infrastructure cash flow can keep funding dividends and projects without l
OpenClear Secure: the identity network has to prove airport scale travels
Clear Secure reported FY2025 revenue of $900.8 million and Q1 2026 revenue of $253.0 million, with the official record tying the thesis to airport-member growth, identity platform expansion, deferred revenue, privacy trust, margin quality and cash conversion.
OpenZipRecruiter, Inc.: the filing proof gates that matter now
ZipRecruiter, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenJoby Aviation: certification progress still has to beat the cash-burn clock
Joby reported 2025 revenue of $53.4 million, a $719.6 million operating loss and latest cash of $874.5 million. The Coverage Bootstrap question is whether certification, manufacturing and air-taxi commercialization can arrive before losses and capital needs di
Open111, Inc.: the filing proof gates that matter now
111, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZillow Group: housing traffic has to become profitable transaction and software proof
ZG has an annual revenue baseline of $2.6B, latest revenue marker of $708M Q1 2026, annual net income of $23M and cash of $678M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.
OpenIONQ: Revenue is scaling, but the quantum proof gate is conversion plus losses.
Q1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
Open